Pharma News

Aflibercept biosimilar by Amgen for Macular Edema: Likelihood of Approval

Photo of MEEFRO MEEFRO Send an email November 18, 2023
0 124,538 Less than a minute

Aflibercept biosimilar is under clinical development by Amgen and currently in Phase III for Macular Edema.

Source link
#Aflibercept #biosimilar #Amgen #Macular #Edema #Likelihood #Approval

Photo of MEEFRO MEEFRO Send an email November 18, 2023
0 124,538 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *